Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
Zeyen T, Böhm L, Paech D, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Schneider-Rothhaar JL, Steinbach JP, Hau P, Kowalski T, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Gkika E, Vatter H, Radbruch A, Herrlinger U, Weller J, Schaub C.
Zeyen T, et al. Among authors: seidel c.
Neuro Oncol. 2024 Oct 1:noae205. doi: 10.1093/neuonc/noae205. Online ahead of print.
Neuro Oncol. 2024.
PMID: 39351820